Trial · NCT00799773
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Role of Rituximab in Increasing Early Treatment Response in Participants With TTP Who Are Also Treated With Plasma Exchange and Corticosteroids | Measured at Day 52 | |
| Secondary | Use of Non-study Treatment | Measured at Month 36 | |
| Secondary | Whether Participants Receiving Rituximab Achieve Early or Late Treatment Response Faster and Require Fewer Plasma Exchanges Than Participants Not Receiving Rituximab | Measured at Days 52 and 82 | |
| Secondary | Relationship Between Clinical and Laboratory Data and Response to Treatment | Measured at Days 52 and 82 | |
| Secondary | Incidence of Relapse Among Participants in the Two Study Groups Who Achieve Early Treatment Response | Measured at Month 36 | |
| Secondary | All Cause Mortality | Measured at Month 36 | |
| Secondary | Treatment-related Complications | Measured at Day 52 | |
| Secondary | Evaluating How Levels of ADAMTS-13 Enzyme and Autoantibody at Specific Time Points or Over the Course of the Study Correlate With Other Indicators of Disease Activity, Remission Rates, Rapidity of Achieving a Remission, and Recurrence Rate | Measured at Month 36 | |
| Secondary | Rituximab Response in Participants With Varying Levels of ADAMTS-13 Activity and Antibodies Against ADAMTS-13 | Measured at Month 36 | |
| Secondary | Effect of Plasma Exchange on Rituximab Levels | Measured at Month 6 | |
| Secondary | Effect of Rituximab Levels on the Extent of B-cell Depletion (CD-19+ Cells) | Measured at Month 12 | |
| Secondary | B-cell Depletion in Relation to ADAMTS-13 Activity and to ADAMTS-13 Antibody Levels and Disease Activity in Participants Who Receive Rituximab Versus Those Who do Not | Measured at Month 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00799773/registered